Literature DB >> 18614394

Many different tumor types have polyclonal tumor origin: evidence and implications.

Barbara L Parsons1.   

Abstract

Few ideas have gained such strong acceptance in the scientific community as the monoclonal origin of tumors; the idea that tumors start with a single mutated cell (or a single clone of cells) that go on to accumulate additional mutations as a tumor develops. The certainty with which this concept is held by the scientific community reflects the length of time it has been unchallenged and the experimental difficulty in obtaining direct evidence to the contrary. Yet, recent findings regarding X chromosome inactivation patch size indicate that the X-linked marker data previously interpreted as evidence of monoclonal tumor origin is actually more consistent with polyclonal tumor origin, a situation where two or more cells or clones of cells interact to initiate a tumor. Although most tumors show homotypy for X-linked markers (as expected given the bias conferred by X chromosome inactivation patch size), the literature contains numerous examples of tumors with X-linked marker heterotypy, examples of which encompass 24 different tumor types. Chimeric models have yielded direct unequivocal demonstrations of polyclonality in rodent and human tumors. Also, mutational data are consistent with polyclonal tumor origin. Methods that analyze levels of tumor-associated oncogene and tumor suppressor gene mutations demonstrate that initiated cells are much more common in normal tissues than previously realized. Also, while tumors have higher levels of mutation than normal tissues, oncogenic mutations frequently are present as subpopulations within tumors, rather than as the pure mutant populations expected to develop from a single initiated cell. Understanding the mutational basis of tumor etiology has important practical significance for assessing cancer risk, as well as in modeling and treating cancer. Therefore, the scientific community needs to re-examine this issue and consider the implications of polyclonal origin for, perhaps, a majority of tumors, encompassing many different tumor types.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18614394     DOI: 10.1016/j.mrrev.2008.05.004

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  29 in total

1.  Monoclonal tumor origin is an underlying misconception of the RESIC approach.

Authors:  Barbara L Parsons
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-14       Impact factor: 11.205

Review 2.  Is Barrett's-Associated Esophageal Adenocarcinoma a Clonal Disease?

Authors:  Nicholas A Wright
Journal:  Dig Dis Sci       Date:  2018-08       Impact factor: 3.199

3.  Transformation of epithelial cells through recruitment leads to polyclonal intestinal tumors.

Authors:  Andrew T Thliveris; Brittany Schwefel; Linda Clipson; Lauren Plesh; Christopher D Zahm; Alyssa A Leystra; Mary Kay Washington; Ruth Sullivan; Dustin A Deming; Michael A Newton; Richard B Halberg
Journal:  Proc Natl Acad Sci U S A       Date:  2013-06-24       Impact factor: 11.205

4.  KRAS mutant tumor subpopulations can subvert durable responses to personalized cancer treatments.

Authors:  Barbara L Parsons; Meagan B Myers
Journal:  Per Med       Date:  2013-03       Impact factor: 2.512

Review 5.  Tumor evolution: Linear, branching, neutral or punctuated?

Authors:  Alexander Davis; Ruli Gao; Nicholas Navin
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2017-01-19       Impact factor: 10.680

6.  Human glioma demonstrates cell line specific results with ATP-based chemiluminescent cellular proliferation assays.

Authors:  Michael E Sughrue; Martin J Rutkowski; Ari J Kane; Andrew T Parsa
Journal:  J Clin Neurosci       Date:  2010-09-09       Impact factor: 1.961

Review 7.  Intratumoral heterogeneity: Clonal cooperation in epithelial-to-mesenchymal transition and metastasis.

Authors:  Deepika Neelakantan; David J Drasin; Heide L Ford
Journal:  Cell Adh Migr       Date:  2014-10-16       Impact factor: 3.405

Review 8.  Turning ecology and evolution against cancer.

Authors:  Kirill S Korolev; Joao B Xavier; Jeff Gore
Journal:  Nat Rev Cancer       Date:  2014-04-17       Impact factor: 60.716

9.  Deconvolving tumor purity and ploidy by integrating copy number alterations and loss of heterozygosity.

Authors:  Yi Li; Xiaohui Xie
Journal:  Bioinformatics       Date:  2014-04-02       Impact factor: 6.937

10.  Discovery of biclonal origin and a novel oncogene SLC12A5 in colon cancer by single-cell sequencing.

Authors:  Chang Yu; Jun Yu; Xiaotian Yao; William K K Wu; Youyong Lu; Senwei Tang; Xiangchun Li; Li Bao; Xiaoxing Li; Yong Hou; Renhua Wu; Min Jian; Ruoyan Chen; Fan Zhang; Lixia Xu; Fan Fan; Jun He; Qiaoyi Liang; Hongyi Wang; Xueda Hu; Minghui He; Xiang Zhang; Hancheng Zheng; Qibin Li; Hanjie Wu; Yan Chen; Xu Yang; Shida Zhu; Xun Xu; Huanming Yang; Jian Wang; Xiuqing Zhang; Joseph J Y Sung; Yingrui Li; Jun Wang
Journal:  Cell Res       Date:  2014-04-04       Impact factor: 25.617

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.